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eluting stent (DES) era.
Methods: We consecutively enrolled acute myocardial infarction (AMI) patients who
underwent percutaneous coronary intervention (PCI) in the COREA-AMI (COnver-
gent REgistry of cAtholic and chonnAm university for AMI) from January 2004 to
December 2009. Of 4,748 AMI patients, 2,607 and 1,617 patients who treated with
only DES were diagnosed with STEMI and NSTEMI, respectively. The primary
endpoint is 30-day all-cause mortality and mortality from 31 days to 5 years. We
performed landmark analysis at 30 days.
Results:Median follow up duration was 43.3 months (interquartile range 29.4 to 59.7
months). All-cause mortality rate at 30 days was higher in STEMI (3.6%; 94 patients)
than NSTEMI (2.4%; 39 deaths; P¼0.031). On the other hand, mortality from 31 days
to 5 years was higher in NSTEMI (17.4% vs. 13.7%; 273 deaths vs. 343 deaths;
P¼0.001). After adjustment with clinical and angiographic characteristics, STEMI is
associated with 30-day mortality (hazard ratio (HR) 1.54, 95% conﬁdence interval
(CI) 1.06-2.25, P¼0.025) and NSTEMI is independent predictor for mortality from 31
days to 5 years (HR 1.26, 95% CI 1.07-1.48, P¼0.006).Conclusions: STEMI was associated with a higher risk of short-term mortality, but
NSTEMI was associated with a higher risk of long-term mortality in the DES era.
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Background: While clinical outcomes undoubtedly favor primary percutaneous
coronary intervention (PPCI) over thrombolysis for ST-elevation Myocardial Infarc-
tion (STEMI), there is paucity of data on the optimal length of hospital stay.
Methods: Between Jan. 2008 and Sep. 2009, a total of 4,549 STEMI patients enrolled
in the Korea Acute Myocardial Infarction Registry(KAMIR) who underwent PPCI
and survived to hospital discharge, were grouped according to the length of stay in
hospital: Group I (short stay, 3 day, n¼809); Group II (medium stay, 4-6 days,
n¼2,263); Group III (long stay, 7 days, n¼1,477). We investigated major adverse
cardiac events (MACEs) at 1, 6, and 12 months and independent predictors of long
stay in hospital.
Results: Group III were signiﬁcant older age (62.8 vs. 63.3 vs. 66.9 years, p< 0.001),
more female (18.3, 22.3, 30.2%, p< 0.001), lower body mass index (BMI) (24.8, 24.2,
23.7, p¼0.001), higher Killip classII (19.9, 26.1, 41.3%, p< 0.001), higher three
vessel disease (14.4, 16.8, 19.6%, p¼0.005), higher prevalence of complication during
PPCI (4.1, 7.7, 18.5%, p< 0.001); higher level of NT-proBNP, lower LV ejection
fraction(EF) (p< 0.001). There were no signiﬁcant difference of MACE at 1, 12
months between Group I, II and III (1 month MACE: 2.4 vs. 1.7 vs. 2.3%, p¼0.475;
12 months: 3.4, 5.6, 3.9%, p¼0.262). In multivariate analysis, independent predictors
of long stay (7 days) in hospital were advanced Killip class II (odds ratio [OR]
1.752; 95% CI, 1.361-2.255, p< 0.001), higher complication rates during PPCI (OR
2.479; 95% CI, 1.737-3.537, p< 0.001), EF < 35% (OR 1.853; 95% CI, 1.142-3.007,
p¼0.013), creatinine > 2.5 mg/dL (OR 3.900; 95% CI, 1.053-14.441, p¼0.042),
higher troponin I (OR 1.698; 95% CI, 1.353-2.132, p< 0.001) and NT-pro BNP
levels(OR 1.946; 95% CI, 1.468-2.580, p< 0.001).
Conclusions: Short length of stay in hospital for low-risk and uncomplicated patients
was similar clinical outcomes and prognosis compared with medium, long stay after
PPCI for STEMI during a 12-month clinical follow-up.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/AcTCT-36
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Background: We evaluated the impact of normal versus high presenting BP on
clinical outcomes and cardiac function in patients with acute ST-elevation myocar-
dial infarction (STEMI) treated with primary percutaneous coronary intervention
(PPCI).
Methods: A total of 12,234 STEMI patients treated with primary percutaneous
coronary intervention (PPCI) were compared according to normal (systolic BP
>90 mmHg and 139 mmHg) versus high (systolic BP 140 mmHg) presenting
BP.
Results: Patients with normal presenting BP (n ¼ 7,647, 62.5%) were associated with
signiﬁcantly higher in-hospital mortality (4.3 vs. 1.8%, p < 0.001), particularly in
patients with prior hypertension, when compared to patients with high presenting
BP (n ¼ 4,587, 37.5%). Patients with normal presenting BP showed higher incidence
of cardiac death (5 vs. 2.6%, p < 0.001) and the composite of major adverse
cardiac events (MACE, deﬁned as all-cause death, myocardial infarction, or re-
vascularizations; 12.2 vs. 10.1%, p < 0.001) at one-year when compared to patients
with high presenting BP. Left ventricular ejection fraction was signiﬁcantly lower in
patients with normal presenting BP at baseline and follow-up (50.7 vs. 51.9%, p <
0.001; 53.6 vs. 54.7%, p ¼ 0.011, respectively). Normal presenting BP was associated
with increased risk of in-hospital mortality (adjusted OR 2.472, CI 1.681-3.635, p <
0.001) in logistic regression analysis. However, it was not associated with cardiac
death (adjusted HR 1.02, CI 0.671-1.55, p¼0.927) and the composite of MACE
(adjusted HR 0.887, CI 0.693-1.135, p ¼ 0.34) at one-year in Cox proportional hazard
regression analysis.
Conclusions: Normal presenting BP, particularly in patients with prior hyper-
tension, was associated with increased in-hospital mortality and lower cardiac
function in STEMI patients treated with PPCI when compared to high presenting
BP. However, outcomes were not different in both groups of patients at one-year
although cardiac function was persistently lower in patients with normal pre-
senting BP.
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Background:We compared the efﬁcacy and safety of sirolimus-eluting stents (SESs),
everolimus-eluting stents (EESs), biodegradable polymer stent (BP-DESs), and
endothelial progenitor cell capture stents (EPCCSs).
Methods: From the IRIS-DES registry, we identiﬁed 1517 patients treated using PCI
with SESs (N ¼ 372), EESs (N ¼ 405), BP-DESs (N ¼ 300), and EPCCSs (N¼440)
in ST-elevation myocardial infarction (STEMI). Major adverse cardiac events
(MACE) were deﬁned using composite of death, myocardial infarction, and target
vessel revasularization at 24 months.
Results: At 2 years, there was no difference in the incidence of MACE (8.5% in
SESs, 9.9% in EES, 10.2% in BP-DES, and 12.8% in EPCCS, P ¼ 0.281), death
(5.0% in SESs, 4.3% in EES, 4.4% in BP-DES, and 6.2% in EPCCS, P ¼ 0.718),
MI (0.6% in SESs, 1.6% in EES, 1.5% in BP-DES, and 1.5% in EPCCS, P ¼
0.572), and TVR (3.8% in SESs, 5.9% in EES, 4.8% in BP-DES, and 6.5% in
EPCCS, P ¼ 0.313). The EPCCSs group showed trend of higher rate in any
revascularization, but no signiﬁcantly statistical difference (6.6% in SESs, 9.1% in
EES, 7.2% in BP-DES, and 11.6% in EPCCS, P ¼ 0.313). The cumulative rates of
deﬁnite stent thrombosis were 0.3% in SESs, 1.2% in EESs, 0.7% in BP-DESs, and
1.6% in EPCCSs (P ¼ 0.239).
Conclusions: The 4 different DESs showed no signiﬁcant difference in clinical
outcome at 2-year follow-up in patients with STEMI.ute Myocardial Infarction B11
